20 articles
Activating three Yamanaka factors — OCT4, SOX2, and KLF4 — appears to reverse epigenetic aging in human eye cells, marking a milestone in rejuvenation medicine.
Epicrispr's GEMS platform silences disease genes epigenetically — reversibly and safely — with a single viral vector, targeting FSHD and beyond.
Boston biotech secures major funding to complete Phase 1 trials of ER-100, a therapy targeting aging through epigenetic reprogramming.
A London startup uses machine learning to stop cells silencing gene therapies, potentially cutting doses and extending treatment durability.
A fractional laser shifted epigenetic markers at 83.9% of aging-linked DNA sites, with visible improvements lasting six months.
Daewoong Pharmaceutical buys Turn Bio's ERA platform, using mRNA to partially reverse cellular aging without tumor risk.
New CRISPR platform quiets PCSK9 cholesterol gene for 18 months in primates — no permanent DNA edits required.
Cells actively remodel their protein factories as we age, potentially triggering disease—but this process could be targeted to slow aging.
Scientists used three Yamanaka factors to help mouse heart muscle cells complete division, reducing scar tissue after heart attacks.
A molecule called OLE restores microglia's protective function, reducing amyloid plaques and improving memory in animal models.
Scribe Therapeutics launches first human trial of STX-1150, an epigenetic therapy silencing PCSK9 to slash LDL without permanently altering DNA.
Cambridge researchers found a gene network that shuts off nerve repair — and an existing hormone drug that reactivates it.
Scribe Therapeutics unveils STX-1150, a liver-targeted epigenetic therapy that durably lowers LDL cholesterol with one dose and no permanent DNA edits.
Researchers artificially induced NREM-like brain patterns in mice, reducing sleep pressure and boosting memory — without actual sleep.
A new MIT-led therapy uses mRNA nanoparticles to rewire immune cells from within, achieving complete tumor regression in most treated mice.
NewLimit's liver-targeting epigenetic reprogramming therapy heads to clinical trials after preclinical results arrived years ahead of schedule.
Serif Biomedicines aims to create a new drug class combining mRNA and gene therapy benefits, targeting rare diseases and immune reprogramming.
Life Biosciences begins groundbreaking human trials testing cellular reprogramming therapy to reverse aging at the cellular level.
Scribe Therapeutics launches first human trial of STX-1150, a reversible epigenetic therapy targeting PCSK9 to lower LDL without altering DNA.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
